A Phase 1 Trial of the Combination of Perifosine and Paclitaxel Given Either Weekly or Every 3 Weeks.
Latest Information Update: 11 Dec 2014
At a glance
- Drugs Paclitaxel (Primary) ; Perifosine (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors AEterna Zentaris Inc
- 17 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 May 2011 Planned end date changed from 1 Dec 2009 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 13 Feb 2009 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.